Preferred Label : rank ligand;
MeSH definition : A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically
binds RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B and OSTEOPROTEGERIN. It plays an
important role in regulating OSTEOCLAST differentiation and activation.;
MeSH synonym : differentiation factor, osteoclast; opgl protein; osteoclast differentiation factor; osteoprotegerin ligand; rankl protein; receptor activator of nuclear factor kappa b ligand; receptor activator of nuclear factor kappab ligand; tnf superfamily, member 11; trance protein; tumor necrosis factor ligand superfamily member 11; tumor necrosis factor-related activation-induced cytokine; Receptor Activator of Nuclear Factor-kappa B Ligand; tumor necrosis factor related activation induced cytokine; receptor activator of nuclear factor-kappab ligand; CD254 Antigen; Antigen, CD254;
Wikipedia link : https://en.wikipedia.org/wiki/Rank ligand;
Is substance : O;
Origin ID : D053245;
UMLS CUI : C0666364;
Allowable qualifiers
Record concept(s)
Related MeSH Supplementary Concept(s)
See also
Semantic type(s)
A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically
binds RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B and OSTEOPROTEGERIN. It plays an
important role in regulating OSTEOCLAST differentiation and activation.
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/xgeva-prostate-1451.html
2012
false
Canada
French
English
Denosumab
evaluation of the transparency committee
fractures, bone
rank ligand
treatment outcome
Cost-Benefit analysis
injections, subcutaneous
denosumab
prostatic neoplasms
bone neoplasms
neoplasm metastasis
antibodies, monoclonal, humanized
drug evaluation
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/xgeva-sein-1626.html
2012
false
Canada
English
French
Denosumab
evaluation of the transparency committee
injections, subcutaneous
treatment outcome
Cost-Benefit analysis
breast neoplasms
neoplasm metastasis
bone neoplasms
fractures, bone
rank ligand
denosumab
drug evaluation
antibodies, monoclonal, humanized
---